Want to see SE:ONCO full AI Analyst Report?
ONCO Stock Chart & Stats
kr1.65
kr0.04(2.18%)
At close: 4:00 PM EDT
kr1.65
kr0.04(2.18%)
Day’s Range― - ―
52-Week Rangekr1.26 - kr5.79
Previous CloseN/A
Volume1.31M
Average Volume (3M)7.53M
Market Cap
kr745.39M
Enterprise Valuekr595.78M
Total Cash (Recent Filing)kr157.61M
Total Debt (Recent Filing)kr135.17M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding431,357,760
10 Day Avg. Volume13,880,346
30 Day Avg. Volume7,533,524
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-18.53
Price to Sales (P/S)15.35
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)kr127.67M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthStrong year-over-year sales growth indicates increasing adoption of Pepaxti across the company’s European commercial footprint. If maintained, the expanding revenue base can improve operating leverage, support investment in commercialization, and move the business closer to covering its fixed cost structure.
Very Strong Gross MarginA 98% gross margin provides substantial contribution from each additional product sale and supports attractive underlying product economics. Combined with controlled operating expenses, this gives revenue growth a clearer path to reducing losses as commercial scale expands across established and newer European markets.
Potential Label ExpansionA successful move into third-line treatment would broaden Pepaxti’s approved use within multiple myeloma and strengthen the product’s commercial runway in Europe. The submitted regulatory variation creates a meaningful growth opportunity, although realization depends on the pending review and decision.
Bears Say
Persistent Operating LossesDespite improving from the prior year, the continuing EBIT loss shows that current product revenue does not yet cover the company’s operating base. Until sales scale further or expenses fall materially, profitability remains unproven and management must execute through a prolonged loss-making phase.
Material Cash BurnSubstantial negative operating and free cash flow means the business is still consuming capital rather than funding growth internally. This raises dependence on liquidity management and external financing, while the stated goal of positive cash flow during 2027 indicates that the transition is not yet complete.
High Financial LeverageDebt remains high relative to the equity base, limiting financial flexibility while the company continues to report losses and negative cash generation. Although the return to positive equity is constructive, elevated leverage can constrain investment choices and increase the consequences of slower-than-expected commercial execution.
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.25 and its highest was kr5.79 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr745.39M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on Aug 27, 2026. The company reported -kr0.144 earnings per share for the quarter.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 431,357,760 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.144 in its last earnings report. Following the earnings report the stock price went up 20.447%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
Immunicum AB
―
Cantargia AB
―
Sprint Bioscience AB
―